Spots Global Cancer Trial Database for abraxane®
Every month we try and update this database with for abraxane® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | NCT01189929 | Pancreatic Canc... | Demcizumab Abraxane® Gemcitabine | 21 Years - | Mereo BioPharma | |
| NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma | NCT03524898 | Soft Tissue Sar... | Nab-Paclitaxel gemcitabine | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | NCT02045589 | Pancreatic Aden... Metastatic Panc... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | NCT02045602 | Locally Advance... Metastatic Soli... Pancreatic Aden... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| Study of SRF617 in Patients With Advanced Solid Tumors | NCT04336098 | Advanced Solid ... | SRF617 Gemcitabine Albumin-Bound P... Pembrolizumab | 18 Years - | Surface Oncology | |
| A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | NCT02045589 | Pancreatic Aden... Metastatic Panc... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma | NCT04528680 | Glioblastoma Gliosarcoma GBM Glioblastoma Mu... Glioblastoma, I... Recurrent Gliob... | Sonication for ... Chemotherapy, a... Chemotherapy, c... | 18 Years - | Northwestern University | |
| A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | NCT01189929 | Pancreatic Canc... | Demcizumab Abraxane® Gemcitabine | 21 Years - | Mereo BioPharma | |
| Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma | NCT02289898 | Pancreatic Canc... | Demcizumab Abraxane® gemcitabine Placebo | 21 Years - | Mereo BioPharma | |
| Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma | NCT04528680 | Glioblastoma Gliosarcoma GBM Glioblastoma Mu... Glioblastoma, I... Recurrent Gliob... | Sonication for ... Chemotherapy, a... Chemotherapy, c... | 18 Years - | Northwestern University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
